Lung cancer is one of the most common malignant tumors in China. Our surveillance data show that the incidence rate of lung cancer is 35.23/100,000 and the mortality rate of lung cancer is 27.93/10 ? million. Lung cancer is mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
As the most authoritative international guideline in the field of SCLC treatment, NCCN publishes 2 editions of clinical practice guidelines on SCLC every year.
The main update points of the guidelines
1. Smoking cessation counseling and interventions were added to the initial assessment.
2. Changed the criteria for unilateral bone marrow aspiration or biopsy: when peripheral blood smear shows nucleated red blood cells, neutropenia or thrombocytopenia, bone marrow aspiration or biopsy is required considering the possible presence of bone infiltration.
3. For extensive stage SCLC in complete or partial remission, the recommended grade for prophylactic brain irradiation (PCI) therapy was reduced from grade 1 to grade 2A ? In addition, chest radiotherapy was added as a treatment option for extensive SCLC.
4. Remove the recommended dose of temozolomide from follow-up treatment; recommend bendamustine as an option for follow-up treatment (Class 2B recommendation)
5.The primary recommended dose of PCI is 25 Gy divided into 10 fractions, once daily. Short-course radiotherapy (20 Gy divided into 5 sessions) is an appropriate option in extensive stage SCLC ? is an appropriate option in extensive SCLC. This edition of the guidelines removes the 30 Gy fractionation of 10 to 15 times and the 24 Gy fractionation of 8 times.
Other updates of less relevance to SCLC have also been made and are not listed here.
Treatment strategy
1. T1-2N0M0 (the only stage suitable for surgery in the guidelines)
Clinical staging of T1-2N0M0, pathological assessment without mediastinal lymph node metastasis, lobectomy (recommended) lymph node dissection or sampling. Postoperative pathology remains (N0) for postoperative adjuvant chemotherapy, if postoperative pathology is (N+) simultaneous chemotherapy + mediastinal radiotherapy.
2. T1-2N0M0 postoperative adjuvant chemotherapy regimen and dose
The recommended regimen is etoposide and cisplatin/carboplatin. The chemotherapy cycle is 4-6.
Cisplatin 60 mg/m2 d1 and etoposide 120 mg/m2 d1,2,3
Cisplatin 80 mg/m2 d1 and etoposide ?100 mg/m2 d1,2,3
Carboplatin AUC 5 to 6 d1 and etoposide 100 mg/m2 d1,2,3
* If postoperative lymph node metastases are found, radiotherapy is required, and the principles of radiotherapy are described below.
3. Other staging (for all patients except T1-2N0M0 surgery)
For patients with inoperable SCLC, radiotherapy is mainly recommended. The main recommended chemotherapy regimen is etoposide and cisplatin/carboplatin or irinotecan and cisplatin/carboplatin. Chemotherapy is administered over a period of 4 to 6 weeks.
Recommended initial chemotherapy regimen and dose.
(1) Limited phase (up to 4-6 cycles).
Cisplatin 60 mg/m2 d1 and etoposide 120 mg/m2 d1,2,3
Cisplatin 80 mg/m2 d1 and etoposide 100 mg/m2 d1,2,3
Carboplatin AUC 5 to 6 d1 and etoposide 100 mg/m2 d1,2,3
During chemotherapy + radiotherapy, cisplatin / etoposide (level 1)* is recommended
* Radiotherapy should be applied no later than 30 days after chemotherapy.
Granulocyte growth factor is not recommended during concurrent radiotherapy.
(2) Extensive phase (up to 4-6 cycles).
Cisplatin 75 mg/m2 d1 and etoposide 100 mg/m2 d1,2,3
Cisplatin 80 mg/m2 d1 and etoposide 80 ?mg/m2 d1,2,3
Cisplatin 25 mg/m2 d1,2,3 and etoposide 100 mg/m2 d1,2,3
Carboplatin AUC 5 to 6 d1 and etoposide 100 mg/m2 d1,2,3
Cisplatin 60 mg/m2 d1 and irinotecan 60 mg/m2 d1,8,15
Cisplatin 30 mg/m2 and irinotecan 65 mg/m2 d1,8
Carboplatin (AUC 5 d1) and irinotecan 50 mg/m2 d1,8,15
4. Second-line treatment after relapse
Preferred clinical trials
(1) Relapse <2 to 3 months, PS = 0 to 2
Paclitaxel, docetaxel, topotecan oral/intravenous, irinotecan, temozolomide, gemcitabine, isocyclophosphamide, bendamustine.
(2) Relapse > 2 to 3 months to 6 months
Topotecan oral/intravenous (level 1), paclitaxel, docetaxel, irinotecan, gemcitabine, vincristine, oral etoposide, temozolomide, cyclophosphamide/adriamycin/vincristine (CAV), bendamustine.
(3) Relapse > 6 months
Apply the original protocol
5. Principles of radiation dose
For limited stage small cell lung cancer, the optimal dose of radiotherapy has not been established uniformly. However, three weeks of 45 Gy (fractionated dose of 1.5 Gy BID) is better than five weeks of 45 Gy (fractionated dose of 1.8 Gy QD).
In the case of BID hyperfractionation, there should be at least a 6-hour interval between treatments to ensure normal tissue repair. If radiotherapy is given once a day, a high dose of 60-70 Gy should be used.
Chest radiotherapy for extensive small cell lung cancer can be used in patients who are sensitive to chemotherapy. Studies have shown that thoracic radiotherapy is well tolerated, reduces recurrence of chest symptoms, and can prolong 2-year survival.
Overall, the overall changes in the NCCN small cell lung cancer guideline update are minor, but of note are the addition of bendamustine to chemotherapy agents and adjustments to the principles of chest radiotherapy and PCI.